Updated: August 12, 2026 | 13-minute read
For a meaningful comparison, the complete protocol must be considered: wavelength, pulse frequency, pulse width, duty cycle, waveform, peak irradiance, time-averaged irradiance, radiant exposure, illuminated area, treatment geometry, session schedule, target population, and intended use. A consumer red light panel should not be assumed equivalent to the targeted headsets, forehead applicators, or combined transcranial and intranasal devices used in published studies.
This guide explains what current evidence supports, what it does not establish, how to calculate pulsed dose correctly, and how to evaluate whether a device can reproduce a defined research protocol. It is educational information, not a recommendation to self-treat a neurological or psychiatric condition.
Why the pulsed-versus-continuous question is different for brain research
Targeted transcranial photobiomodulation device and tissue attenuation diagram
Transcranial photobiomodulation applies red or near-infrared optical energy to the head with the aim of influencing superficial cortical or related physiological processes. The brain is a distinct target because neural activity can be measured through outcomes such as electroencephalography (EEG), cerebral blood flow, oxygenation, metabolism, cognition, and mood.
However, several mechanisms commonly discussed in tPBM are not unique to the brain. Mitochondrial signaling, changes involving cytochrome c oxidase, nitric oxide, cellular redox state, and local blood flow are also studied in other tissues. What is more specific to brain research is the possibility that time-varying light delivery may interact with neural activity or alter EEG patterns.
That possibility should not be confused with proof of frequency-specific entrainment. A study can show that EEG changed after a pulsed intervention without proving that the brain synchronized directly to the programmed pulse frequency. Demonstrating entrainment or a frequency-specific effect requires an appropriate comparison between frequencies, continuous output, and sham while other variables are controlled.
Continuous wave and pulsed wave: the parameters that actually matter
Continuous and pulsed optical output with complete dose parameters
Continuous-wave output provides light without intentional on/off cycling during the exposure. Pulsed-wave output alternates between on and off states according to a defined waveform. Neither mode inherently delivers more energy: the result depends on the actual optical output and exposure time.
For an ideal rectangular pulse with zero optical output during the off phase:
Time-averaged irradiance:
Average irradiance (mW/cm²) = Peak irradiance (mW/cm²) × Duty cycle
Radiant exposure:
Radiant exposure (J/cm²) = Average irradiance (mW/cm²) × Exposure time (seconds) ÷ 1000
or, when the reported value is confirmed to be peak irradiance:
Radiant exposure (J/cm²) = Peak irradiance × Duty cycle × Exposure time ÷ 1000
For example, a verified peak irradiance of 100 mW/cm² at a 50% duty cycle produces a time-averaged irradiance of approximately 50 mW/cm². Over 600 seconds, the incident radiant exposure is approximately 30 J/cm².
If the manufacturer has already reported a time-averaged pulsed irradiance, the duty cycle must not be applied again. Doing so would undercalculate dose. If the device still emits light during the nominal off phase, the simple peak-times-duty-cycle formula also needs adjustment.
Why peak irradiance is not enough
Peak irradiance describes the optical intensity during the on phase. It does not by itself describe energy per pulse or total session dose. Energy per pulse depends on peak irradiance and pulse width, while total radiant exposure depends on the time-averaged irradiance and session duration.
A complete pulsed specification therefore needs all of the following:
- optical pulse frequency in Hz;
- pulse width in milliseconds or microseconds;
- duty cycle as a percentage;
- waveform shape;
- off-state optical output;
- peak irradiance at the treatment plane;
- time-averaged irradiance at the same plane;
- exposure time and resulting radiant exposure;
- measurement distance, area, instrument, and uncertainty.
If duty cycle or pulse width is missing, it should not be estimated as 50%. The correct response is to request the waveform data or measure the optical output with a suitable photodetector and oscilloscope.
What the brain research supports—and what it does not
Researcher reviewing tPBM protocol and EEG data
The evidence base for tPBM includes mechanistic research, animal experiments, studies in healthy participants, small clinical trials, and a growing number of randomized studies. The field is active, but protocols remain heterogeneous and the evidence for any single "best" frequency is limited.
The 40 Hz Zomorrodi study
Zomorrodi and colleagues published a randomized, sham-controlled, double-blind crossover pilot study in 2019 involving 20 healthy adults. The active device delivered 810 nm near-infrared light at 40 Hz and a 50% duty cycle for 20 minutes through four targeted scalp modules plus one intranasal applicator.
The study reported changes in EEG power and network measures after active treatment compared with sham. It provides evidence that this complete 810 nm, 40 Hz, targeted transcranial-plus-intranasal protocol affected measured neural activity.
It does not establish that:
- 40 Hz is universally optimal;
- pulsed light is superior to continuous light;
- the observed changes were caused specifically by the pulse frequency;
- a standard panel positioned near the head can reproduce the protocol; or
- EEG changes demonstrate clinical benefit.
The study used one active pulse frequency and did not include a CW or alternative-frequency active comparison. Its authors described the findings as preliminary and called for confirmatory research.
The 10 Hz Saltmarche case series
Saltmarche and colleagues reported a 2017 case series involving five people with mild to moderately severe dementia or possible Alzheimer's disease. The protocol used 810 nm light pulsed at 10 Hz and combined weekly transcranial-plus-intranasal treatment with daily intranasal treatment over 12 weeks.
The reported cognitive and functional improvements are hypothesis-generating, but the study was uncontrolled, included only five participants, and used a combined intervention. It cannot isolate the effect of 10 Hz, the transcranial component, the intranasal component, or placebo and expectation effects. It therefore should not be used as the basis for advising consumers to select 10 Hz on a general-purpose panel.
Direct comparisons of pulsed and continuous output
A 2023 randomized, sham-controlled study by Tang and colleagues compared sham, CW, 40 Hz pulsed, and 100 Hz pulsed tPBM at 660 nm and 850 nm in 56 healthy young adults. The intervention lasted eight minutes, and the reported mean power density was held at 250 mW/cm². The study found that pulsed output produced distinct acute cognitive and EEG effects under some tested conditions.
This is relevant direct-comparison evidence, but it remains a short study in healthy participants with multiple wavelength and mode groups. It does not establish a clinical treatment standard for dementia, depression, sleep disorders, traumatic brain injury, or other neurological conditions.
The most defensible conclusion is that pulsed and continuous tPBM may produce different effects under specific protocols. The available evidence does not support a universal instruction to "pulse for the brain."
What 10 Hz and 40 Hz labels really mean
Ten hertz falls within the commonly defined alpha EEG range, while 40 Hz falls within the gamma range. This makes both values scientifically interesting, but matching a stimulus frequency to a named EEG band does not prove that the stimulus will entrain that band or improve a clinical outcome.
The Zomorrodi study defined delta as 1–3 Hz, theta as 4–7 Hz, alpha as 8–14 Hz, beta as 14–30 Hz, and gamma as 30–50 Hz. Therefore:
- 10 Hz is an alpha-range stimulus, not a delta-range stimulus;
- 40 Hz is a gamma-range stimulus; and
- a device output of 11.4 Hz would still fall within the cited alpha range, although it would not precisely reproduce a 10 Hz research setting.
Protocol replication requires frequency accuracy, but the acceptable tolerance must come from the device specification, validation plan, or study design—not from an assumption that any value inside a broad EEG band is equivalent.
Why a standard red light panel is not automatically a tPBM research device
Published tPBM studies have used headsets, forehead applicators, laser probes, LED clusters, helmets, and combined transcranial and intranasal systems. These devices differ from general-purpose panels in several important ways:
- the emitters are positioned over defined anatomical sites;
- contact or near-contact geometry reduces distance uncertainty;
- the illuminated area and beam profile are controlled;
- hair, scalp curvature, skull thickness, and placement affect delivery;
- wavelength and optical dose are specified for the exact applicator;
- the device may have a research-specific sham mode; and
- safety and intended use are defined for that configuration.
A panel specification such as "200 mW/cm² at 15 cm" describes optical output at a surface measurement plane. It does not state how much energy reaches a cortical target, whether the value is a center-point or spatial average, or whether the device reproduces the placement and dose used in a tPBM study.
Surface irradiance is an important starting measurement, but wavelength, anatomy, beam geometry, illuminated area, positioning, and tissue attenuation all affect deeper delivery. Electrical wattage and LED count are not substitutes for these optical data.
How to read a device specification sheet for protocol matching
Complete photobiomodulation specification sheet with measurement callouts
1. Match the exact wavelength—not a generic "red and NIR" label
Human tPBM research has used wavelengths including approximately 800, 810, 830, 850, and 1064 nm, among others. There is no universal requirement that a brain-oriented protocol include 850 nm, and the two frequently cited 10 Hz and 40 Hz studies above both used 810 nm.
Wavelength selection should follow the complete study or validated device protocol being considered. A 660/850 nm panel should not be presented as equivalent to an 810 nm targeted device solely because both include near-infrared light.
2. Confirm what the irradiance number represents
The report should identify whether irradiance is:
- peak or time-averaged;
- measured in CW or pulsed mode;
- a center-point value or an average across a defined grid;
- measured with one channel or all channels enabled;
- recorded before or after thermal stabilization; and
- tied to a stated distance, beam angle, active area, and calibrated instrument.
Without these details, a headline value cannot support a reliable dose calculation.
3. Verify the optical waveform, not only the programmed setting
The displayed value on a control screen is an electronic command. Pulse fidelity should be evaluated from the optical output using a photodetector and oscilloscope. The report should show measured frequency error, pulse width, duty cycle, rise and fall times, off-state leakage, and stability during a full session.
CE, FCC, ETL, or an ISO 13485 certificate does not replace this optical measurement.
4. Do not transfer protocols between devices by frequency alone
A 10 Hz setting on two devices may involve different wavelengths, duty cycles, peak outputs, illuminated areas, and pulse widths. Even when the programmed frequency is identical, the delivered radiant exposure and tissue geometry can be very different.
The REDDOT RDPRO 1500-ULTRA public specification, for example, lists 660 nm and 850 nm output, irradiance above 200 mW/cm² at six inches, and an adjustable 0–40 Hz pulse range. Those values identify available device features; they do not by themselves establish a brain protocol or equivalence to an 810 nm research headset. A protocol evaluation would still need to confirm pulse width, duty cycle, optical frequency tolerance, enabled wavelength channels, whether the irradiance is peak or time-averaged, spatial uniformity, and the model's intended use.
5. Check the intended use and instructions for use
A device can have accurate optical output but still lack an intended use for transcranial or neurological applications. For professional procurement, the regulatory status, labeling, contraindications, and clinical evidence must match the exact model and the claims being made in the destination market.
What standards and certifications do—and do not—prove
Standards and test scope comparison for a photobiomodulation device
IEC 62471
IEC 62471 provides exposure limits, reference measurement methods, and a risk-group framework for the photobiological safety of lamps and lamp systems, including LEDs. It can support an optical hazard assessment when the report identifies the exact model, operating mode, distance, geometry, and configuration tested.
It does not prove therapeutic efficacy, neurological suitability, pulse accuracy, electrical safety, or safe use under every possible condition. It should be described as a photobiological safety assessment or report, not as evidence that the treatment works.
ETL, electrical safety, EMC, FCC, and CE documentation
ETL listing indicates compliance with the applicable safety standards identified in the listing record. FCC requirements address radiofrequency emissions and related equipment authorization obligations. CE marking indicates conformity with the applicable European requirements and conformity-assessment route.
The precise meaning depends on the standard, report scope, product category, and model. None of these marks automatically verifies optical pulse frequency, duty cycle, wavelength accuracy, irradiance uniformity, or clinical benefit.
ISO 13485
ISO 13485 is a quality management system standard for organizations involved in medical-device design and manufacture. Certification can support confidence that defined processes, records, risk controls, corrective actions, and change controls are managed within the certified scope.
It is not a product-performance certificate. It does not independently prove that a particular panel outputs exactly 10.0 Hz, that every production unit has identical irradiance, or that a device is effective for a neurological condition. Those claims require product-specific specifications, verification records, acceptance criteria, and test data.
FDA establishment registration and device listing
FDA establishment registration and device listing are administrative regulatory requirements for applicable facilities and devices. The FDA explicitly states that registration and listing do not denote approval, clearance, authorization, certification, or endorsement.
For a US procurement or marketing claim, the relevant question is the exact device's regulatory pathway, classification, exemption or premarket status, labeling, and intended use—not whether the manufacturer has an establishment registration number.
Health Canada licensing
A Health Canada Medical Device Licence applies to the devices and intended purposes within its defined scope. It should not be generalized to every product made by the same company or to an unlisted neurological use. Buyers should verify the licence status, device identifiers, class, manufacturer, and licensed intended use in the official database.
A practical decision framework
Professional protocol-matching workflow for transcranial photobiomodulation
If you are reviewing published research
Start with the study population and device geometry, then record every optical and treatment parameter. Do not reduce a protocol to "10 Hz" or "40 Hz." Note whether the study compared pulse frequencies, compared pulsed with CW, used sham, measured during or after exposure, and evaluated physiological or clinical outcomes.
EEG modulation is not the same endpoint as improved cognition, symptom relief, or disease treatment.
If you are procuring a device for a clinic or research program
Request documentation for the exact model and configuration:
- intended use and instructions for use;
- wavelength spectrum and tolerance;
- optical waveform measurements at each intended setting;
- pulse width, duty cycle, peak and average irradiance;
- spatial irradiance map at the treatment plane;
- thermal stability across the full exposure time;
- model-specific electrical, EMC, and photobiological safety reports;
- applicable market authorization or conformity documentation; and
- production acceptance criteria and change-control records.
If a research protocol requires 810 nm at 40 Hz and 50% duty cycle with targeted placement, a 660/850 nm panel with an adjustable frequency control does not reproduce it automatically.
If you are an OEM or private-label brand
Define the complete optical protocol before design freeze. The specification should include tolerances and verification methods for wavelength, pulse frequency, pulse width, duty cycle, off-state output, peak and average irradiance, spatial uniformity, thermal stability, and treatment geometry.
Claims such as cognitive enhancement, dementia support, depression treatment, or neurological rehabilitation can change the device's intended use and regulatory obligations. They should not be added to a general wellness panel solely because the controller includes 10 Hz or 40 Hz settings.
If you are considering personal use near the head
Do not construct a brain protocol from frequency alone or copy parameters from a study that used different hardware. Follow the exact device instructions and seek qualified medical guidance before using light for a neurological, psychiatric, cognitive, or sleep-related condition.
The cited Zomorrodi study excluded people with a history of seizures. Its safety observations therefore should not be generalized to that population. Questions involving photosensitivity, medications, eye conditions, implanted devices, or other medical factors should be assessed using the specific device labeling and appropriate professional advice rather than a generic online contraindication list.
Safety considerations for head-proximity use
Safety depends on wavelength, spectral radiance, irradiance, exposure time, viewing geometry, distance, pulse characteristics, and the user's individual circumstances.
- Avoid staring directly into high-intensity LEDs and follow the model-specific eye-safety instructions.
- Do not assume that closed eyes or generic goggles make every exposure safe; protective measures must match the device's spectrum and assessed hazard.
- Confirm whether the device's photobiological safety report covers the actual operating mode and distance being used.
- Monitor comfort and surface temperature; pulsing does not automatically eliminate thermal effects.
- Do not treat a neurological or psychiatric condition without appropriate clinical oversight.
- Use the device only within its labeled intended use and contraindications.
Blanket claims such as "all implanted electronic devices are a hard contraindication" or "all direct ocular PBM is prohibited" are too broad without device-specific labeling. Conversely, the existence of specialized ophthalmic PBM research does not make direct exposure from a high-output consumer panel appropriate. The exact device and exposure conditions matter.
Key takeaways
- There is no universal best pulse frequency for brain applications.
- Ten hertz is in the alpha range; 40 Hz is in the gamma range. Band matching does not prove entrainment or clinical benefit.
- The frequently cited 40 Hz study tested one targeted 810 nm pulsed protocol against sham, not against CW or another active frequency.
- The frequently cited 10 Hz dementia report was an uncontrolled five-person case series using combined transcranial and intranasal devices.
- Peak irradiance, duty cycle, pulse width, time-averaged irradiance, exposure time, and radiant exposure must be evaluated together.
- Never assume a 50% duty cycle when it is not reported.
- A standard panel should not be treated as equivalent to a research tPBM device.
- IEC 62471, ETL, FCC, CE documentation, ISO 13485, and FDA registration each have limited and different meanings; none automatically proves pulse fidelity or neurological efficacy.
- Match the complete validated protocol and the exact intended use—not only the Hz value.
FAQ
Should red light therapy be pulsed for the brain?
Not as a universal rule. Pulsed tPBM has produced measurable effects in specific studies, while continuous tPBM has also been used in human brain research. The appropriate mode depends on the complete validated protocol. Current evidence does not justify a simple instruction to use pulsed output for all brain-related goals.
Is 10 Hz or 40 Hz better?
Neither has been established as universally better. Ten hertz and 40 Hz have been studied under different devices, wavelengths, placements, populations, doses, and schedules. They cannot be compared as isolated numbers. Ten hertz lies in the alpha EEG range, while 40 Hz lies in the gamma range, but that correspondence alone does not establish neural entrainment or therapeutic benefit.
Is peak irradiance more important than average irradiance?
They answer different questions. Peak irradiance describes the on phase. Pulse width and peak irradiance determine energy per pulse, while time-averaged irradiance and exposure time determine total incident radiant exposure. A reproducible protocol needs both, together with waveform, frequency, and treatment geometry.
Is 850 nm required for transcranial photobiomodulation?
No. Published human research has used several red and near-infrared wavelengths, including approximately 800, 810, 830, 850, and 1064 nm. The cited 10 Hz and 40 Hz studies used 810 nm. Match the exact wavelength and device geometry of the protocol being evaluated rather than treating 850 nm as a universal requirement.
Can a full-size red light panel reproduce a tPBM study?
Not automatically. Research devices often use defined scalp positions, contact or near-contact delivery, controlled beam areas, and sometimes an intranasal component. A panel at a distance can differ substantially in wavelength, geometry, dose distribution, and intended use. Equivalence requires documented comparison, not visual similarity or a matching frequency setting.
Is there scientific evidence for tPBM?
Yes. Peer-reviewed human and preclinical studies report effects on EEG, cerebral physiology, cognition, mood, and other outcomes. However, device designs and protocols vary widely, and evidence for specific clinical indications or a universally superior pulse frequency remains incomplete. Physiological changes should not automatically be presented as proven treatment benefits.
References
- Hamblin MR. Shining light on the head: Photobiomodulation for brain disorders. BBA Clinical. 2016;6:113–124.
- Zomorrodi R, et al. Pulsed Near Infrared Transcranial and Intranasal Photobiomodulation Significantly Modulates Neural Oscillations: a pilot exploratory study. Scientific Reports. 2019;9:6309.
- Saltmarche AE, et al. Significant Improvement in Cognition in Mild to Moderately Severe Dementia Cases Treated with Transcranial Plus Intranasal Photobiomodulation: Case Series Report. Photomedicine and Laser Surgery. 2017;35(8):432–441.
- Tang L, Jiang H, Sun M, Liu M. Pulsed transcranial photobiomodulation generates distinct beneficial neurocognitive effects compared with continuous wave transcranial light. Lasers in Medical Science. 2023;38:203.
- Spera V, et al. Pilot Study on Dose-Dependent Effects of Transcranial Photobiomodulation on Brain Electrical Oscillations. Journal of Alzheimer's Disease. 2021;83(4):1481–1498.
- Montazeri K, Chaibakhsh S, Fekrazad R. Effects of transcranial photobiomodulation in cerebral circulation and brain neural oscillations: a systematic review. Lasers in Medical Science. 2025;40:341.
- International Electrotechnical Commission. IEC 62471:2006—Photobiological safety of lamps and lamp systems.
- U.S. Food and Drug Administration. Important Reminders about Registration and Listing.
- International Organization for Standardization. ISO 13485—Medical devices quality management systems.
- Intertek. ETL Listed Mark.
- Health Canada. How medical devices are licensed and regulated.
- World Association for Photobiomodulation Therapy. WALT Recommendations.
- REDDOT LED. RDPRO 1500-ULTRA public product specifications.